To learn about our parent company, Takeda Pharmaceutical Company Limited, please visit http://www.takeda.com/
Please contact us at US.corporatecommunications@takeda.com or (224) 554-5499.
U.S. Food and Drug Administration Accepts New Drug Application for Review, Grants Priority Review for Takeda’s TAK-721 (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis
TAKEDA FURTHER ENABLES HEMOPHILIA A PERSONALIZED CARE WITH LAUNCH OF MYPKFIT® SOFTWARE FOR ADYNOVATE ® [ANTIHEMOPHILIC FACTOR (RECOMBINANT), PEGYLATED]
Takeda to Highlight Research Commitment in Bleeding Disorders and Personalized Care at American Society of Hematology (ASH) Virtual Annual Meeting
Takeda to Present Rare Bleeding Disorders Research at Thrombosis & Hemostasis Summit of North America (THSNA) 2020
National Hemophilia Foundation and Takeda Partner with Alex Borstein to Raise Awareness of von Willebrand Disease
SEE ALL NEWS AND RELEASES >